Jiangbo Pharmaceuticals, Inc.

On August 31, 2017, Jiangbo Pharmaceuticals, Inc. went out of business as per its Chapter 7 liquidation filing under bankruptcy. Jiangbo Pharmaceuticals, Inc. engages in the research, development, manufacture, marketing, & sale of pharmaceutical products & health supplements in China. It offers tablets, capsules, granules, syrups, mixtures, & pillselectuary and oral solutions for Western medical drugs and Chinese herbal-based drugs. The company’s western pharmaceutical products include Clarithromycin Sustained-release tablets for curing Clarithromycin sensitive microorganism infection; Itopride Hydrochloride granules for curing digestive system-related disease; Ciprofloxacin Hydrochloride tablets for curing infection caused by bacteria; Paracetamol tablets used for relief of fever, headache, and joint pain; and Felodipine Sustained-released tablets, used to treat hypertension & patients with angina. Its Chinese herbal-based pharmaceutical products comprise Baobaole Chewable tablets for gastric cavity aches; Radix Isatidis Disperable tablets for curing virus influenza & sour throat; Kang Gu Sui Yan Pian tablets for curing bone & bone marrow inflammation; Gan Mao Zhi Ke Ke Li, which helps to relieve cold and flu symptoms; Yi Mu Cao Gao that is used to treat dysmenorrhoea, oligminorrhea, and postpartum abdominal pains; Ban Lan Gen Ke Li to cure viral influenza; Gan Mao Zhi Ke Tang Jiang, a syrup to relieve cold and flu symptoms; and New Compound Foliumisatidis tablets, which cures influenza. The company sells its products to hospitals, medical institutions, and over the counter retail pharmacies through distributors and salespeople. The company was formerly known as Genesis Pharmaceuticals Enterprises, Inc. and changed its name to Jiangbo Pharmaceuticals, Inc. in April 2009. Jiangbo Pharmaceuticals, Inc. was founded in 2003 and is based in Yantai, China.